APAC IPOs & Placements, Aequitas Research

Ethan Aw

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Balaji Speciality Chemicals / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/balaji-speciality-chemicals" target="_blank" data-smartkarma-citation="entities:36270:1" rel="noopener">Balaji Speciality Chemicals (1742663D IN)</a> is looking to raise about US$126m in its upcoming India IPO. </li>
<li>Balaji Speciality Chemicals (BSC) is the sole manufacturer in India of niche chemicals such as Ethylenediamine, Piperazine (Anhydrous), Diethylenetriamine, Amino Ethyl Ethanol Amines and Amino Ethyl Piperazine, according to CRISIL.</li>
<li>BSC’s profitability growth has been stupendous, given its quick production ramp up. However, its growth is very likely to normalize. </li>
</ul>



Balaji Speciality Chemicals (1742663D IN) is looking to raise about US$126m in its upcoming India IPO. 
Balaji Speciality Chemicals (BSC) is the sole manufacturer in India of niche chemicals such as Ethylenediamine, Piperazine (Anhydrous), Diethylenetriamine, Amino Ethyl Ethanol Amines and Amino Ethyl Piperazine, according to CRISIL.
BSC’s profitability growth has been stupendous, given its quick production ramp up. However, its growth is very likely to normalize. 


Balaji Speciality Chemicals Pre-IPO - Stupendous Growth but Likely to Normalize

<ul>
<li>
<a href="https://www.smartkarma.com/entities/balaji-speciality-chemicals" target="_blank" data-smartkarma-citation="entities:36270:1" rel="noopener">Balaji Speciality Chemicals (1742663D IN)</a> is looking to raise about US$126m in its upcoming India IPO. The deal will be run by JM Financial and HDFC Bank. </li>
<li>Balaji Speciality Chemicals (BSC) is the sole manufacturer in India of niche chemicals such as Ethylenediamine, Piperazine (Anhydrous), Diethylenetriamine, Amino Ethyl Ethanol Amines and Amino Ethyl Piperazine, according to CRISIL.</li>
<li>The chemicals it manufactures are import substitutes and are used in end-use industries such as speciality chemicals. Its customer base grew from 45 in FY20 to 182 in FY22.</li>
</ul>



Balaji Speciality Chemicals (1742663D IN) is looking to raise about US$126m in its upcoming India IPO. The deal will be run by JM Financial and HDFC Bank. 
Balaji Speciality Chemicals (BSC) is the sole manufacturer in India of niche chemicals such as Ethylenediamine, Piperazine (Anhydrous), Diethylenetriamine, Amino Ethyl Ethanol Amines and Amino Ethyl Piperazine, according to CRISIL.
The chemicals it manufactures are import substitutes and are used in end-use industries such as speciality chemicals. Its customer base grew from 45 in FY20 to 182 in FY22.


Balaji Speciality Chemicals Pre-IPO Tearsheet

India

Mankind Pharma Limited develops and delivers pharmaceutical products. The Company distributes antibiotic, antifungal, antiviral, gastrointestinal, cardiovascular, dermal, erectile dysfunction, digestive, gynecological, and therapeutic medical drugs. Mankind Pharma operates in India.

Balaji Speciality Chemicals (1742663D IN)

Balaji Speciality Chemicals (1742663D IN)

Balaji Speciality Chemicals Pre-IPO - Stupendous Growth but Likely to Normalize

Balaji Speciality Chemicals (1742663D IN) is looking to raise about US$126m in its upcoming India IPO. BSC’s profitability growth has been...

Ethan Aw

Balaji Speciality Chemicals Pre-IPO Tearsheet

Balaji Speciality Chemicals (1742663D IN) is looking to raise about US$126m in its upcoming India IPO. The deal will be run by JM Financial and...

Ethan Aw